Pentalgin, 24 pcs.

Pharmacotherapeutic group: analgesic (analgesic non-narcotic + non-steroidal anti-inflammatory drug + psychostimulant + antispasmodic + H₁-histamine receptor blocker).

ATX code: N02VE71

Pharmacological properties

Combined drug, has analgesic, anti-inflammatory, antispasmodic, antipyretic effect.

Paracetamol is a non-narcotic analgesic which has antipyretic and analgesic effect caused by blockade of cyclooxygenase in the central nervous system and by influence on the centers of pain and thermoregulation.

Naproxen is non-steroidal anti-inflammatory drug which has anti-inflammatory, analgesic and antipyretic effect due to non-selective inhibition of cyclooxygenase activity which regulates synthesis of prostaglandins.

Caffeine causes dilatation of blood vessels in skeletal muscles, heart, kidneys; it increases mental and physical performance, eliminates fatigue and sleepiness; it increases permeability of histohematic barriers and increases bioavailability of non-narcotic analgesics, thus enhancing therapeutic effect. It has a tonic effect on cerebral vessels.

Drotaverine has myotropic antispasmodic effect caused by inhibition of phosphodiesterase IV and acts on smooth muscles in the gastrointestinal tract, biliary tract, genitourinary and vascular systems.

Pheniramine is a blocker of H1-histamine receptors. It has antispasmodic and mild sedative effects, reduces the phenomena of exudation, and enhances the analgesic effect of paracetamol and naproxen.

Indications

Pain syndrome associated with smooth muscle spasm, including chronic cholecystitis, cholelithiasis, post-cholecystectomy syndrome, renal colic.

Post-traumatic and postoperative pain syndrome, including those accompanied by inflammation.

Active ingredient

Composition

Active ingredients:

paracetamol – 325.0 mg,

naproxen – 100.0 mg,

caffeine anhydrous-50.0 mg,

drotaverine hydrochloride-40.0 mg,

pheniramine maleate-10.0 mg.

Auxiliary substances: microcrystalline cellulose – 128.0000 mg,potato starch – 55.3800 mg,croscarmellose sodium – 32.0000 mg,hyprolose (hydroxypropyl cellulose) – 32.5200 mg,citric acid monohydrate – 3.0000 mg,butylhydroxytoluene (H 321) – 0.3000 mg, magnesium stearate – 7.2000 mg, talc – 16.

Shell: hypromellose (hydroxypropyl methylcellulose) – 12.1700 mg, povidone (polyvinylpyrrolidone with medium molecular weight medical, povidon-K25) -3.8700mg, polysorbate-80 (tween-80) – 1.1000 mg, titanium dioxide – 3.4300 mg, talc – 4.2180 mg, quinoline yellow dye (E 104) – 0.2000 mg, indigo carmine (E 132)-0.0127 mg,

or

How to take, the dosage

Ingestion.

The drug is taken 1 tablet 1-3 times a day. Maximum daily dose is 4 tablets.

The treatment duration is not more than 3 days as an antipyretic and not more than 5 days as an analgesic. It is possible to continue treatment with the drug only after consulting a doctor.

Do not exceed the stated dose!

Interaction

Combined administration of the drug with barbiturates, tricyclic antidepressants, rifampicin and alcohol-containing beverages should be avoided (increased risk of hepatotoxic effect).

Paracetamol increases the effect of indirect anticoagulants and reduces the effectiveness of uricosuric drugs.

Long-term use of barbiturates reduces the effectiveness of paracetamol.

The concomitant use of paracetamol with ethanol increases the risk of acute pancreatitis.

Microsomal oxidation inhibitors (including cimetidine) reduce the risk of hepatotoxic effects of paracetamol.

Diflunisal increases the plasma concentration of paracetamol by 50%, which increases the risk of hepatotoxicity.

Naproxen may decrease the diuretic effect of furosemide, increase the effect of indirect anticoagulants, increase sulfonamides and methotrexate toxicity, decrease lithium excretion and increase its concentration in plasma.

The co-administration of caffeine and barbiturates, primidone, anticonvulsants (hydantoin derivatives, especially phenytoin) may increase the metabolism and clearance of caffeine; concomitant use of caffeine and cimetidine, oral contraceptives, disulfiram, ciprofloxacin, norfloxacin decreases caffeine metabolism in the liver (slowing its excretion and increasing blood concentrations).

The simultaneous use of caffeine-containing drinks and other central nervous system stimulants may lead to overstimulation of the central nervous system.

Concomitant use of drotaverine may impair the antiparkinsonian effect of levodopa.

Concomitant use of pheniramine with tranquilizers, hypnotics, monoamine oxidase inhibitors, alcohol may increase the depressant effect on the central nervous system.

Special Instructions

The concomitant use of the drug with other drugs containing paracetamol and/or other non-steroidal anti-inflammatory drugs, as well as with the means for relief of symptoms of “colds”, flu and nasal congestion should be avoided.

When using the drug for more than 5-7 days, peripheral blood parameters and the functional state of the liver should be monitored.

Paracetamol distorts the results of laboratory studies of plasma glucose and uric acid.

If it is necessary to determine 17-ketosteroids, the drug should be canceled 48 hours before the study. Note that naproxen increases bleeding time.

The effect of caffeine on the central nervous system depends on the type of nervous system and may manifest as excitation or inhibition of higher nervous activity.

Periods of alcoholic beverages should not be consumed during treatment.

Impact on the ability to drive vehicles and mechanisms

Contraindications

With caution cerebrovascular diseases, diabetes, peripheral arterial disease, gastrointestinal ulcers in the anamnesis, mild to moderate renal and hepatic insufficiency, Viral hepatitis, alcoholic liver damage, benign hyperbilirubinemia (Gilbert, Dubin-Johnson, and Rotor syndrome), epilepsy and proneness to seizures, glucose-6-phosphate dehydrogenase deficiency, advanced age.

Side effects

Allergic reactions: skin rash, itching, urticaria, angioedema;

Blood disorders: thrombocytopenia, leukopenia, agranulocytosis, anemia, methemoglobinemia;

Nervous system disorders: agitation, anxiety, increased reflexes, tremor, headache, sleep disturbances, dizziness, decreased concentration;

Cardiovascular system disorders: palpitations, arrhythmias, increased blood pressure;

Gastrointestinal system: erosive-ulcerative lesions of the gastrointestinal tract, nausea, vomiting, discomfort in the epigastrium, abdominal pain, constipation, liver function disorder;

Urinary system: Impaired renal function;

Senses: decreased hearing, tinnitus, increased intraocular pressure in patients with closed-angle glaucoma;

Others: dermatitis, tachypnoea (rapid breathing).

If any of the side effects listed in the instructions worsen, or if you notice any other side effects not listed in the instructions, tell your doctor.

Overdose

Symptoms: Skin pallor, anorexia (lack of appetite), abdominal pain, nausea, vomiting, gastrointestinal bleeding, agitation, motor restlessness, confusion, tachycardia, arrhythmia, hyperthermia (increased body temperature), rapid urination, headache, tremor or muscle twitching; epileptic seizures, increased activity of “hepatic” transaminases, hepatonecrosis, increased prothrombin time.

The symptoms of liver dysfunction may appear 12-48 hours after overdose. In severe overdose liver failure with progressive encephalopathy, coma, death; acute renal failure with tubular necrosis; arrhythmia, pancreatitis develop. If an overdose is suspected, immediate medical attention should be sought.

Treatment: gastric lavage followed by activated charcoal. A specific antidote for paracetamol poisoning is acetylcysteine. Administration of acetylcysteine is relevant for 8 hours.

In case of gastrointestinal bleeding, antacids and gastric lavage with ice-cold 0.9% sodium chloride solution; maintenance of ventilation and oxygenation; in epileptic seizures, intravenous diazepam; maintenance of fluid and salt balance.

Pregnancy use

The drug is contraindicated for use during pregnancy. If it is necessary to use the drug during lactation, breastfeeding should be stopped.